A phase 1 study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of SC-002, an ADC directed against DLL3 and conjugated with PBD, in patients with advanced SCLC and large-cell neuroendocrine carcinoma. Here, DLL3 is linked to small cell lung carcinoma.